The extracellular basement membrane of choice for researchers who wish to mimic more in vivo like environments.
KRAS is one of the most frequently mutated oncogenes in human cancers, playing a critical role in tumor initiation, progression, and therapeutic resistance. Mutations such as KRAS G12C, G12D, G12V, and G13D are commonly observed in lung, colorectal, and pancreatic cancers, making KRAS a high-value but historically challenging drug target. TargetMol provides KRAS-related products, including a comprehensive range of small-molecule inhibitors, biochemical tools, and research reagents designed to ...